{
  "docId": "019de073-d2da-762c-9a26-b97a59cfec30",
  "docSlug": "f7af69768ee002be4e2317aa5e807561",
  "documentTitle": "Revelation Biosciences | Investor Presentation Deck | 18 slides",
  "authorId": "revelation-biosciences",
  "authorName": "Revelation Biosciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 6,
  "pageCount": 18,
  "prevPage": 5,
  "nextPage": 7,
  "slideType": "key_messages",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 3,
  "notes": "Includes a medical illustration of IV administration and clinical mechanism.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-d2da-762c-9a26-b97a59cfec30/6",
  "deckHref": "/decks/019de073-d2da-762c-9a26-b97a59cfec30",
  "deckJsonHref": "/decks/019de073-d2da-762c-9a26-b97a59cfec30.json",
  "deckAnchorHref": "/decks/019de073-d2da-762c-9a26-b97a59cfec30#slide-6",
  "components": [
    {
      "bbox": {
        "h": 0.3,
        "w": 0.25,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "image",
      "text": "Medical illustration of IV administration",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "90156204-daa5-4d7d-a608-12f8a8a0461e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.05,
        "y": 0.85
      },
      "kind": "list",
      "text": "Next Step: Initiate Ph1a/Ph1b study - Planning in progress",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "23e587d7-9901-486a-bedf-d5297eaabc2e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.55,
        "x": 0.38,
        "y": 0.18
      },
      "kind": "list",
      "text": "Scientific Rationale: Stimulation of the TLR-4 TRIF pathway with REVTx-100: Augments immune cell recruitment; Downregulates pro-inflammatory response. Preclinical studies show reduction of post-surgical infection.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "77256f38-f8eb-454b-b7a2-ffe266af1787",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.45,
        "x": 0.45,
        "y": 0.65
      },
      "kind": "list",
      "text": "Market: Large Market potential: ~3% of hospital patients suffer HAI (~687,000 annual cases, ~72,000 deaths).",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c2adbbc7-4ff4-4a32-871f-12cdd6e6fa69",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.35,
        "x": 0.05,
        "y": 0.65
      },
      "kind": "list",
      "text": "Intellectual Property: US 11,389,654 (Licensed from Vanderbilt University); Additional related applications anticipated.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ecacd7a4-865e-4b22-8dc2-f7a1b97e4d04",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.3,
        "x": 0.17,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "1. 2015 HAI and Antibiotic Use Prevalence Survey, CDC.gov",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "78b1e7f8-8bc4-4480-adf6-06bfd4eb536f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.35,
        "x": 0.04,
        "y": 0.05
      },
      "kind": "title",
      "text": "REVTx-100 Program Highlights",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "13301f39-0d6a-482d-bc4b-2c1d01efd45f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 15,
      "from": 4,
      "beatId": "2182d072-e6b9-49a0-b466-5a839998139b",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "Slides 4-15 describe various solutions, including PHAD, REVTx-100, REVTx-200, and REVDx-501.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 15,
      "from": 4,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "f450b0af-f83a-4370-8b16-ab5011fb13d6",
      "evidence": "Slides 4-15 describe PHAD and its applications.",
      "position": 1,
      "objective": "Why is PHAD a well-defined TLR4 agonist with multiple potential applications?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}